TC-2402-038-SP
Проводит Takeda
Страница компанииTachoSil® Versus Current Practice in Dura Sealing Techniques for the Prevention of Post-operative Cerebrospinal Fluid (CSF) Leaks in Patients Undergoing Skull Base Surgery: An Open Label, Randomised, Controlled, Multi-centre, Parallel Group Efficacy and Safety Trial.
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT01355627/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: от 18 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 726 чел. во всех странах исследования.
- Плановая дата окончания (06.2013) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 9 · невключение: 18
Критерии включения
- Main Inclusion Criteria (Positive response):
- Is the surgical approach/procedure consistent with skull base surgery? I.e. one of the following:
- Lateral approach to the foramen magnum: Far lateral, extreme lateral, anterolateral, posterolateral
- Approach to the jugular foramen: Infratemporal, juxta condylar, transjugular
- Approach to the cerebello pontine (CP) angle and petrous apex retrosigmoid
- Approach to the middle fossa: Subtemporal (+/- petrous apex drilling), pterional approach (any fronto temporal approach +/- orbitozygomatic deposition)
- Approach to the anterior fossa: Subfrontal (uni or bilateral)
- Approach to the midline posterior fossa
- Main
Критерии невключения
- (Negative response):
- Has the patient been subject to neurosurgery involving opening of the dura mater within the last 3 months?
- Is the patient anticipated to undergo any additional neurosurgery involving opening of the dura mater which may affect the efficacy evaluation (e.g. re-operation or anticipation to undergo several neurosurgeries) before the Efficacy Follow-up Week 7±1 week?
- Is the patient anticipated to undergo any additional neurosurgery involving opening of the dura mater which may affect the safety evaluation (e.g. re-operation or anticipation to undergo several neurosurgeries) before the Safety Follow-up Week 28±2 weeks?
- The surgical approach/procedure is consistent with any transcranial or transfacial or combination of transcranial - transfacial approaches with wide defect in the skull base? I.e. any of the following:
- Trans basal approach
- Total petrosectomy
- Trans facial approach
- Trans sphenoidal approach
- Endoscopic procedures
- Trans oral approach (and any extension: Le Fort, mandibulotomy)
- The surgical approach is consistent with one of the following approaches?
- Translabyrinthine approach
- Retrolabyrinthine approach
- Transcochlear (limited transpetrosal) approach
- Did the arachnoid membrane and the CSF containing system remain intact during surgery?
- Does the patient have more than one dura opening (not including dura openings from extraventricular or lumbar drains)?
- Has TachoSil, fibrin or polymer sealants been used during the current surgery prior to randomization?
Источник: ClinicalTrials.gov, NCT01355627 · запись обновлена в реестре 25 июля 2014.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 1
- Percentage of Participants With Clinically Evident Verified Post-Operative Cerebrospinal Fluid Leak or Clinically Evident Pseudomeningocele or Treatment Failure — Up to 8 Weeks (7 Weeks ± 1 Week)
Цель исследования
The primary objective is to demonstrate superiority of TachoSil® compared to current practice as an adjunct in sealing the dura mater. The efficacy of the dura mater sealing must be evaluated post-operatively. The secondary objective is to evaluate the safety of TachoSil® as an adjunct in sealing the dura mater.
The trial population will consist of 726 randomised (1:1) patients elected for skull base surgery. The trial duration consists of screening, surgery, efficacy follow-up after 7±1 weeks and safety follow-up 28±2 weeks after surgery.
Где проходит
0 центровЦентры в реестре не указаны.
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT01355627 Официальный реестр (США) · загружено 9 ноября 2026Номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.